Why Is Biktarvy So Expensive? US vs World Price 2026

If you have looked at a US pharmacy price for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), the number is hard to believe: about $4,216 a month. The same single-tablet HIV regimen, made by the same manufacturer, costs a fraction of that in the United Kingdom, Canada, and most of Europe. So why is Biktarvy so expensive in the United States — and what does the gap actually mean for you?

SunnyPharma provides this educational guide to explain the real reasons behind Biktarvy’s US price, compare it against published prices in other countries, and walk through the legitimate ways US patients lower what they pay. The price gap is real and worth understanding — but as you will see, the most reliable way to cut your cost is usually a US program, not a plane ticket.

Why Biktarvy Costs So Much in the United States

Three structural features of the US market — not any property of the drug itself — drive Biktarvy’s price.

1. Patent protection and no generic competition

Gilead Sciences holds US patent protection on bictegravir, Biktarvy’s key active ingredient, with exclusivity extending into the 2030s per the FDA Orange Book. As long as those patents stand, no company can sell a competing generic in the US. Generic competition is the single most powerful force that lowers drug prices — and for Biktarvy, it does not yet exist domestically. A brand-name manufacturer with no generic rival has little market pressure to lower its price.

2. The US does not negotiate or cap most drug prices

This is the difference that matters most. In nearly every other wealthy country, a single national payer — the NHS in the UK, provincial drug plans in Canada, national health systems across Europe — negotiates one price for the entire country, and regulators can refuse to cover a drug priced too high. Canada goes further: its Patented Medicine Prices Review Board caps what manufacturers may charge for patented drugs.

The United States has no equivalent for most medications. Manufacturers set their own list price, and historically the federal government was barred from negotiating Medicare drug prices at all. That is beginning to change — Biktarvy was selected for Medicare price negotiation in 2026 — but the structural default in the US remains manufacturer-set pricing.

3. Specialty tiers and the middle layers

What you encounter as a patient is the list price, or wholesale acquisition cost (WAC) — $4,216 per month as of January 2026. Per Milliman’s drug-pricing reference, WAC is the manufacturer’s published price before discounts and rebates, not the net price anyone actually receives. Between that list price and your pharmacy counter sit pharmacy benefit managers, wholesalers, and insurers — each negotiating rebates and adding margin. Insurers then place Biktarvy on their highest specialty tier, which often means paying a percentage of the drug’s cost rather than a flat copay. The result is a system where the headline number is enormous and what any individual pays is wildly variable.

The US pays more for the same Biktarvy not because the drug is different, but because no single payer negotiates the price down and no generic competition forces it down.

Biktarvy Cost in Other Countries: A Price Comparison

The numbers below are published health-system prices — what national formularies and public drug plans pay — drawn from official sources. They show the size of the gap. They are not the price an individual would pay to import the drug, and they are not an invitation to do so (see the legal section below).

USD conversions are approximate as of June 2026 and move with exchange rates; the native-currency figures are the sourced values. UK and Canada figures are the same brand-name Gilead product at a negotiated health-system price. The India figure is a licensed generic, a different product category.

Europe and the UK

Across Western Europe, Biktarvy is the identical Gilead product, sold at prices negotiated by each national health system. The UK’s NHS indicative price is £879.51 for 30 tablets per the official NHS Dictionary of Medicines and Devices — roughly a quarter of the US list price. For patients treated within the NHS, HIV medication is provided free at the point of care regardless of the list price.

Canada

Canada’s public drug plans negotiate prices province by province, within national caps. Ontario’s formulary lists Biktarvy at CAD $1,176.68 per month per the Toronto General Hospital Immunodeficiency Clinic’s published regimen cost reference — about US $860 at current exchange rates, again the same brand-name product the US pays $4,216 for.

India

India is a different category. There, Biktarvy’s active ingredients are produced as licensed generics under Gilead’s voluntary licensing through the Medicines Patent Pool, at roughly $150 per month. Because this involves the legality and safety questions specific to generics and importation, we cover it in a dedicated guide rather than repeating it here.

Why Is It Cheaper Abroad? The Real Reasons

It is tempting to assume the cheaper drug abroad must be lower quality, or that Americans are subsidizing the world. The honest picture is narrower:

• It is the same drug. In the UK, Canada, and Europe, Biktarvy is the identical Gilead-manufactured product. Only the price the health system pays differs.
• One buyer, one negotiation. A national health system negotiates a single price for an entire population and can walk away. That bargaining power is something no individual US insurer fully matches.
• Price regulation. Bodies like Canada’s price review board legally cap patented-drug prices. The US has no comparable cap for most drugs.
• No middle-layer markup stack. Single-payer systems largely bypass the pharmacy-benefit-manager and rebate machinery that adds cost and complexity in the US.

None of this means the US drug is “worth more.” It means the US has chosen a pricing system that produces higher prices for the same medicine.

Can You Legally Buy Biktarvy From Another Country?

This is the question the price gap naturally raises, and the answer requires care.

Two further cautions matter for a medication you depend on every day:

• Supply-chain safety. Counterfeit and substandard medicines are a documented risk when buying outside verified channels. The FDA publishes guidance on buying medicines safely online. An HIV regimen that is underdosed or counterfeit can allow viral rebound and resistance.
• Clinical continuity. If you ever obtain medication outside your usual care pathway, tell your clinician so they can monitor your viral load and confirm the product is appropriate.

This guide does not provide instructions for importing Biktarvy and does not recommend any source. If price is what is driving you to consider it, the US options below can usually bring your cost to $0 — legally, safely, and often faster.

What Actually Lowers Your Biktarvy Cost in the US

Here is the part that matters most: for most patients, the cheapest and safest Biktarvy is available inside the US system, not abroad. The international price gap is a useful argument for drug-pricing reform — but it is rarely the right personal strategy when these programs exist.

Each of these is explained in detail, with eligibility and how to apply, in our main cost guide.

Will Biktarvy Ever Get Cheaper in the US?

Two developments could narrow the gap, on very different timelines.

Medicare price negotiation (sooner, but limited). In January 2026, Biktarvy was selected for Medicare price negotiation under the Inflation Reduction Act — the first HIV medication ever chosen. A negotiated “Maximum Fair Price” is expected to take effect in 2028. Crucially, it would apply only to Medicare Part D — not commercial insurance, not the uninsured cash price. Source: Positively Aware, Jan 2026.

Generic competition (later, and decisive). The price will not broadly fall until generic bictegravir can enter the US market, which cannot happen while Gilead’s patents stand. Until then, the US list price is likely to keep drifting upward — Gilead raised Biktarvy’s list price by roughly 5.9% at the start of 2025 (Pharmacy Times).

Frequently Asked Questions

What to Do Today